NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 381.05 Million USD | -9.91% |
| 2022 | 422.97 Million USD | 0.67% |
| 2021 | 420.15 Million USD | 8.32% |
| 2020 | 387.86 Million USD | 47.64% |
| 2019 | 262.71 Million USD | 56.36% |
| 2018 | 168.02 Million USD | 38.38% |
| 2017 | 121.41 Million USD | 231.69% |
| 2016 | 36.6 Million USD | 193.39% |
| 2015 | 12.47 Million USD | 128.77% |
| 2014 | 5.45 Million USD | 63.0% |
| 2013 | 3.34 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 104.81 Million USD | 3.54% |
| 2024 Q2 | 115.7 Million USD | 10.39% |
| 2024 Q3 | 119.72 Million USD | 3.48% |
| 2023 FY | 381.05 Million USD | -9.91% |
| 2023 Q2 | 92.03 Million USD | -0.58% |
| 2023 Q3 | 95.22 Million USD | 3.47% |
| 2023 Q4 | 101.22 Million USD | 6.3% |
| 2023 Q1 | 92.56 Million USD | -7.01% |
| 2022 Q1 | 109.82 Million USD | 6.08% |
| 2022 Q3 | 101.24 Million USD | -9.89% |
| 2022 Q4 | 99.54 Million USD | -1.69% |
| 2022 FY | 422.97 Million USD | 0.67% |
| 2022 Q2 | 112.36 Million USD | 2.32% |
| 2021 Q4 | 103.52 Million USD | 0.12% |
| 2021 FY | 420.15 Million USD | 8.32% |
| 2021 Q1 | 108.31 Million USD | -6.48% |
| 2021 Q2 | 104.91 Million USD | -3.13% |
| 2021 Q3 | 103.4 Million USD | -1.45% |
| 2020 FY | 387.86 Million USD | 47.64% |
| 2020 Q4 | 115.81 Million USD | 11.08% |
| 2020 Q3 | 104.26 Million USD | 15.27% |
| 2020 Q2 | 90.45 Million USD | 16.96% |
| 2020 Q1 | 77.33 Million USD | 3.87% |
| 2019 Q4 | 74.44 Million USD | 7.64% |
| 2019 Q1 | 53.49 Million USD | 14.68% |
| 2019 Q2 | 65.6 Million USD | 22.64% |
| 2019 FY | 262.71 Million USD | 56.36% |
| 2019 Q3 | 69.16 Million USD | 5.42% |
| 2018 Q3 | 45.8 Million USD | 9.9% |
| 2018 Q1 | 33.88 Million USD | -10.87% |
| 2018 FY | 168.02 Million USD | 38.38% |
| 2018 Q4 | 46.64 Million USD | 1.83% |
| 2018 Q2 | 41.68 Million USD | 23.0% |
| 2017 Q1 | 23.21 Million USD | 20.48% |
| 2017 Q2 | 25.22 Million USD | 8.65% |
| 2017 Q4 | 38.02 Million USD | 8.77% |
| 2017 Q3 | 34.95 Million USD | 38.58% |
| 2017 FY | 121.41 Million USD | 231.69% |
| 2016 Q1 | 5.07 Million USD | -16.58% |
| 2016 Q3 | 10.55 Million USD | 517.31% |
| 2016 Q4 | 19.26 Million USD | 82.54% |
| 2016 Q2 | 1.71 Million USD | -66.28% |
| 2016 FY | 36.6 Million USD | 193.39% |
| 2015 Q1 | 1.31 Million USD | 11.96% |
| 2015 FY | 12.47 Million USD | 128.77% |
| 2015 Q3 | 3.29 Million USD | 83.71% |
| 2015 Q2 | 1.79 Million USD | 36.77% |
| 2015 Q4 | 6.07 Million USD | 84.55% |
| 2014 FY | 5.45 Million USD | 63.0% |
| 2014 Q1 | 925 Thousand USD | 0.0% |
| 2014 Q2 | 1.57 Million USD | 70.7% |
| 2014 Q3 | 1.78 Million USD | 13.24% |
| 2014 Q4 | 1.17 Million USD | -34.51% |
| 2013 FY | 3.34 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 56.3 Million USD | -576.775% |
| AngioDynamics, Inc. | 154.69 Million USD | -146.324% |
| AtriCure, Inc. | 300.37 Million USD | -26.863% |
| Avinger, Inc. | 2 Million USD | -18924.363% |
| Azenta, Inc. | 263.14 Million USD | -44.812% |
| BioLife Solutions, Inc. | 46.75 Million USD | -715.062% |
| The Cooper Companies, Inc. | 2.35 Billion USD | 83.839% |
| Daxor Corporation | 1.1 Million USD | -34433.64% |
| Ekso Bionics Holdings, Inc. | 9.07 Million USD | -4097.136% |
| Femasys Inc. | 691.9 Thousand USD | -54974.064% |
| GlucoTrack, Inc. | -13 Thousand USD | 2931315.385% |
| Harvard Bioscience, Inc. | 60.86 Million USD | -526.061% |
| Hologic, Inc. | 2.22 Billion USD | 82.895% |
| ICU Medical, Inc. | 739.87 Million USD | 48.497% |
| Intuitive Surgical, Inc. | 4.72 Billion USD | 91.943% |
| KORU Medical Systems, Inc. | 16.7 Million USD | -2180.653% |
| LeMaitre Vascular, Inc. | 127.04 Million USD | -199.93% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 319433.942% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 319433.942% |
| Masimo Corporation | 1 Billion USD | 62.027% |
| Microbot Medical Inc. | -106 Thousand USD | 359588.679% |
| Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | -1051.406% |
| Merit Medical Systems, Inc. | 583.87 Million USD | 34.736% |
| Nephros, Inc. | 8.4 Million USD | -4433.706% |
| NEXGEL, Inc. | 619 Thousand USD | -61460.258% |
| NEXGEL, Inc. | 619 Thousand USD | -61460.258% |
| Singular Genomics Systems, Inc. | -558 Thousand USD | 68389.964% |
| OraSure Technologies, Inc. | 179.42 Million USD | -112.382% |
| Pro-Dex, Inc. | 14.55 Million USD | -2518.775% |
| Pulse Biosciences, Inc. | -1.2 Million USD | 31670.671% |
| Predictive Oncology Inc. | 1.14 Million USD | -33171.544% |
| Precision Optics Corporation, Inc. | 5.79 Million USD | -6472.485% |
| QuidelOrtho Corporation | 1.49 Billion USD | 74.501% |
| Repligen Corporation | 315.22 Million USD | -20.883% |
| Sanara MedTech Inc. | 57.13 Million USD | -566.918% |
| STAAR Surgical Company | 252.65 Million USD | -50.824% |
| Sharps Technology, Inc. | -891.24 Thousand USD | 42855.552% |
| Utah Medical Products, Inc. | 30.03 Million USD | -1168.586% |
| DENTSPLY SIRONA Inc. | 2.08 Billion USD | 81.733% |
| Jin Medical International Ltd. | 6.78 Million USD | -5516.32% |